BOSTON, MA - Jul 10, 2017 - Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15th of July in Boston, MA. Following the success of last year?s inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Society?s Annual Meeting and Exposition from the 16th to 18th of July.
The symposium schedule has been designed to provide an overview of the latest developments in nanomedicine research, including strategies for overcoming in vitro and in vivo barriers to effective and targeted drug delivery. It will cover a diverse range of applications, with the keynote address - To target or not to target: lessons from RNAi-based targeted lipid nanoparticles - being provided by Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. Other topics covered during the symposium will explore cutting-edge research in the fields of gene therapy, genetic vaccines and small molecule delivery. This will include industry talks from GSK, CureVac and Genentech, as well as presentations from the Beth Israel Deaconess Medical Centre, the University of British Columbia and Houston Methodist/Weill Cornell Medical College.
The symposium will also give attendees a chance to explore the latest enabling technologies in the nanomedicines sector - with presentations from Precision NanoSystems and event sponsors Spectradyne, SpectrumLabs, Malvern Instruments and Sigma-Aldrich - as well as providing networking opportunities throughout the day.
For those unable to attend the event in person, you can still enjoy a virtual front row seat via a free livestream.Register nowto join the event online.
About Precision NanoSystems
Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases. PNI’s NanoAssemblr™ Transfection Reagents use nanomedicine technology to deliver genetic materials in primary cells in vitro and in vivo, enabling disease researchers to easily study gene function in high-value models of disease. PNI’s proprietary NanoAssemblr™ platform enables the rapid, reproducible, and scalable manufacture of nanoparticle formulations for delivery of nucleic acids, drug molecules, and diagnostic agents to cells and tissues in the body. PNI sells its products to leading pharmaceutical and biotechnology companies, and leading academic institutions in over 20 countries worldwide.
